The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Guidance for community oncologists navigating the AML treatment landscape
Yakir Moshe, MD, PhD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, provides advice to community oncologists outside large academic centers who are navigating the increasingly complex landscape of acute myeloid leukemia (AML) treatment. Dr Moshe highlights the value of pooling data, discussing patient care, and staying up to date with the latest research. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The best advice for maybe community centers or small centers treating a lower volume of patients with AML is to network. Pool data, pool efforts, discuss your patients, monitor the results of your care and what you’re doing. And of course, stay up to date with the data. So we’ve published our results regarding really the bits and pieces of patient management. And other groups have also published theirs...
The best advice for maybe community centers or small centers treating a lower volume of patients with AML is to network. Pool data, pool efforts, discuss your patients, monitor the results of your care and what you’re doing. And of course, stay up to date with the data. So we’ve published our results regarding really the bits and pieces of patient management. And other groups have also published theirs. One of the things we showed in the REVIVE study is that as time progressed, when we look at the first 50 patients that we treated versus the second group of 50 to the last group, our results regarding overall survival have been improving as time on study went by. So when we gain experience with ven-aza protocols, our results get better. So we gained experience, you know, from our work, but I think there is much to do from gaining from other people’s experience. So, you know, disseminating our knowledge and everyone’s knowledge and gathering that up is essential for good patient care.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
